GUILLAIN-BARRE SYNDROME AFTER SOLID ORGAN TRANSPLANTATION

Autor: Rafik A. El-Sabrout, Van Buren Ct, B. Radovancevic, Ankoma-Sey

Publikováno v: Transplantation. 71:1311-1316

Background. Neurological complications occur frequently in solid organ transplant recipients. However, the peripheral nerves are usually spared significant toxicity. Guillain Barre syndrome (GBS) is the most common cause of acute neuropathy in adults

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4a3521ede9cab7265ff8e8ac27322e9
https://doi.org/10.1097/00007890-200105150-00023

Right atrial bypass grafting for central venous obstruction associated with dialysis access: Another treatment option

Autor: Rafik A. El-Sabrout, J. Michael Duncan

Publikováno v: Journal of Vascular Surgery. 29:472-478

Purpose: Central venous obstruction is a common problem in patients with chronic renal failure who undergo maintenance hemodialysis. We studied the use of right atrial bypass grafting in nine cases of central venous obstruction associated with upper

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::081f43ec603bc2cbc1ba218147657bd3
https://doi.org/10.1016/s0741-5214(99)70275-2

Initial results of solitary pancreas transplants performed without regard to donor/recipient HLA mismatching

Autor: Ronald H. Kerman, Phebe Chen, Rafik A. El-Sabrout, James H. Clark, Stephen M. Katz, Scott A. Gruber, Bruce Kaplan

Publikováno v: Transplantation. 70(2)

BACKGROUND We hypothesized that solitary pancreas transplants could be performed successfully even in the presence of poor HLA matching if an aggressive approach were taken with regard to immunosuppressive protocol and the performance of allograft bi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::63717a2ed4844e613f0468552cd02645
https://pubmed.ncbi.nlm.nih.gov/10933170

Novel Once-Daily Extended-Release Tacrolimus Versus Twice-Daily Tacrolimus in De Novo Kidney Transplant Recipients: Two-Year Results of Phase 3, Double-Blind, Randomized Trial

Autor: Lionel Rostaing, Suphamai Bunnapradist, Josep M. Grinyó, Kazimierz Ciechanowski, Jason E. Denny, Helio Tedesco Silva, Klemens Budde, Sanjay Kulkarni, Donald Hricik, Barbara A. Bresnahan, Rafik A. El-Sabrout, Laurence K. Chan, Gaetano Ciancio, Mohamed A. El-Ghoroury, Michael J. Goldstein, Robert S. Gaston, Reginald Y. Gohh, Mary T. Killackey, Anne King, Richard J. Knight, Arputharaj H. Kore, Debra L. Sudan, Javier Chapochnick Friedmann, Shamkant P. Mulgaonkar, Charles Nolan, Oleh G. Pankewycz, John D. Pirsch, Heidi M. Schaefer, Steven M. Steinberg, Bruce E. Gelb, Karin A. True, Patricia M. West-Thielke, Mary M. Waybill, Joshua H. Wolf, Beverley L. Ketel, Robert C. Harland, Fuad S. Shihab, Elisabeth Cassuto, Yannick Le Meur, Christophe Mariat, Josep Maria Grinyó, Jose Puig, Daniel Seron, Giuseppe Tisone, Bartosz Foroncewicz, Zbigniew Wlodarczyk, Oliver Witzke, Guillermo A. Mondragon, Eduardo Mancilla Urrea, Josefina Alberu Gomez, Rafael Reyes Acevedo, Maria del Carmen Rial, Pablo A. Novoa, Helio T. Silva, Valter D. Garcia, Deise D. Carvalho, Luciana T. Santamaria Saber, Fabiana L. Contieri, Marcos G. Bastos, Roberto C. Manfro, John Kanellis, Josette Eris, Philip O’Connell, Peter Hughes, Graeme Russ, Grant B. Pidgeon, Ian D. Dittmer, Terence Kee, Anantharaman Vathsala, Radomir Naumovic, Igor Mitic, Randhawa Parmjeet

Publikováno v: American Journal of Kidney Diseases. (4):648-659

Background1-year data from this trial showed the noninferiority of a novel once-daily extended-release tacrolimus (LCPT; Envarsus XR) to immediate-release tacrolimus (IR-Tac) twice daily after kidney transplantation.Study DesignFinal 24-month analysi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::52de67cbb5744401dbcd18959497af8e